JON DEID

JON DEID

Kymera weakness says a purchase opportunity, stifel

[ad_1] Stifel Analyst Alex Thompson repeats a purchase rating in Kymera therapeutics (Kymr) The partner Sanofi’s decision, including “Updates Slide,” (Cut off) Leader IRAK4 DEGRADER KT-474, coordinate with the next Gen KT-485 and Gilead with a new partnership dealDice) for…